FDA Approves Eli Lilly’s Cymbalta To Treat Chronic Musculoskeletal Pain

The Food and Drug Administration Nov. 4 approved Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.

Cymbalta, which is manufactured by Indianapolis-based Eli Lilly and Co., was first approved to treat major depressive disorder in 2004.

FDA said the recommended dose for Cymbalta is a 60 mg capsule taken once daily without regard to meals. The capsule should be swallowed whole, and not chewed, crushed or opened; the contents should never be sprinkled on food or mixed with liquids, the agency said.

“Up to three quarters of the population experience chronic ...